Medicamen Organics Ltd IPO 2026
| Metric | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Revenue | 2528.96 | 2296.24 | 2118.67 |
| Profit After Tax | 240.41 | 95.78 | 9.23 |
| EBITDA | — | — | — |
| Net Worth | 1518.40 | 851.71 | 755.92 |
| Total Assets | 3858.07 | 3211.98 | 2707.21 |
| Reserves & Surplus | 658.40 | 251.71 | 155.92 |
| Total Borrowings | 1265.65 | 1179.50 | 1024.57 |
Medicamen Organics Limited was incorporated in 1995 and develops, manufactures, and distributes pharmaceutical dosages including generic dosages in the form of tablets, capsules, oral liquids, ointments, gels, syrups, suspensions and dry powders for the Government (including State Governments and Central Governments) and private entities as a contract manufacturer/third party manufacturer.
The company's product list comprises 84 products and offers a wide range of drugs such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, proton pump inhibitors, antihistamines, antihypertensive drugs, lipid preparations, antiparasitics, multivitamin preparations, multimineral and non-steroidal anti-inflammatory drugs (NSAIDS).
The company's products are marketed throughout India as well as in African, CIS, and South East Asian countries such as Congo, Benin, Kameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya through third-party distributors.
The company has two WHO-GMP-approved manufacturing facilities in Haridwar, Uttarakhand, covering an area of 21,536 Sq. Ft. As on September 30, 2023, the company has entered into contract manufacturing with 38 domestic partners and 12 merchant exporters.
As of September 30, 2023, the company employed a total of 116 people.